



**CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

**TERRABIOGEN TECHNOLOGIES INC.**

(Expressed in Canadian Dollars)

**For the nine months ended March 31, 2017**

(Unaudited – Prepared by Management)

Notice: These consolidated interim financial statements have been prepared by management and they have not been reviewed by the Company's external auditors

## **NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

The accompanying unaudited condensed consolidated interim financial statements of TerraBioGen Technologies Inc. for the nine months ended March 31, 2017 have been prepared by management of the Company and approved by the Company's Audit Committee and the Company's Board of Directors.

Under National Instrument 51-102, Part 4, subsection 4.3 (3)(a), if an auditor has not performed a review of the consolidated interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these interim financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

**TERRABIOGEN TECHNOLOGIES INC.**  
**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION**  
(Expressed in Canadian Dollars)  
(Unaudited – Prepared by management)

	<b>March 31, 2017</b>	June 30, 2016
<b>ASSETS</b>		
Current		
Cash	\$ 165,009	\$ 176,855
Amounts receivable	6,103	6,257
Inventory	4,829	4,829
Deposits and prepaid expenses	3,355	19,953
<b>CURRENT ASSETS</b>	<b>179,296</b>	207,894
Property and equipment	131,480	179,977
Long term assets	47,355	47,355
<b>TOTAL ASSETS</b>	<b>\$ 358,131</b>	<b>\$ 435,226</b>
<b>LIABILITIES</b>		
Current		
Accounts payable and accrued expenses	\$ 279,165	\$ 322,394
<b>CURRENT LIABILITIES</b>	<b>279,165</b>	322,394
Provision for dismantling	6,407	6,251
<b>TOTAL LIABILITIES</b>	<b>285,572</b>	328,645
<b>SHAREHOLDERS' EQUITY</b>		
Share capital (Note 4)	40,019,549	39,656,113
Commitment to issue shares	288,000	-
Contributed surplus	2,462,323	2,405,759
Deficit	(42,697,313)	(41,955,291)
<b>SHAREHOLDERS' EQUITY</b>	<b>72,559</b>	106,581
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>\$ 358,131</b>	<b>\$ 435,226</b>

Nature of Operations and Going Concern (Note 1)  
Commitments (Note 6)

Signed on its behalf by:

"Blair Heffelfinger"  
Director

"Theodore Deuel"  
Director

*The accompanying notes are an integral part of these condensed consolidated interim financial statements.*

**TERRABIOGEN TECHNOLOGIES INC.**  
**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS**  
For the Nine Months ended March 31  
(Expressed in Canadian Dollars)  
(Unaudited – prepared by management)

	<b>Nine months 2017</b>	Nine months 2016	<b>Three months 2017</b>	Three months 2016
<b>REVENUE</b>				
Sale of products	\$ -	\$ 3,320	\$ -	\$ -
Other income	-	1,400	-	1,219
<b>TOTAL REVENUE</b>	<b>-</b>	<b>4,720</b>	<b>-</b>	<b>1,219</b>
<b>COST OF PRODUCTS SOLD</b>	<b>-</b>	<b>398</b>	<b>-</b>	<b>-</b>
<b>GROSS PROFIT</b>	<b>-</b>	<b>4,322</b>	<b>-</b>	<b>1,219</b>
<b>EXPENSES</b>				
Administration	<b>303,955</b>	333,088	<b>109,613</b>	115,758
Research and development	<b>435,152</b>	475,412	<b>149,958</b>	162,690
<b>TOTAL EXPENSES</b>	<b>739,107</b>	808,500	<b>259,571</b>	278,448
Loss before other items	<b>(739,107)</b>	(804,178)	<b>(259,571)</b>	(277,229)
Other items:				
Interest income	<b>14</b>	312	-	73
Interest expense	<b>(2,929)</b>	(2,037)	<b>(838)</b>	(825)
Gain on sale of asset	-	3,593	-	3,685
<b>TOTAL OTHER ITEMS</b>	<b>(2,915)</b>	1,868	<b>(838)</b>	2,933
<b>NET LOSS AND COMPREHENSIVE LOSS</b>	<b>\$ (742,022)</b>	\$ (802,310)	<b>\$ (260,409)</b>	\$(274,296)
<b>BASIC AND DILUTED LOSS PER SHARE</b>				
	<b>\$ (0.37)</b>	\$ (0.44)	<b>\$ (0.13)</b>	\$ (0.15)
<b>WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</b>				
	<b>1,988,053</b>	1,840,391	<b>2,030,046</b>	1,897,511

*The accompanying notes are an integral part of these condensed consolidated interim financial statements.*

**TERRABIOGEN TECHNOLOGIES INC.**  
**CONSOLIDATED INTERIM STATEMENTS OF SHAREHOLDERS' DEFICIT**  
For the Periods Ended March 31  
(Expressed in Canadian Dollars)

	<u>Common shares</u>		Commitment to Issue Shares	Contributed Surplus	Accumulated Deficit	Total
	Number of Shares	Amount				
Balance at July 1, 2015	1,771,511	\$ 38,572,901	\$ 70,000	\$ 2,229,619	\$ (40,833,904)	\$ 38,616
Shares issued for cash	126,000	840,000	-	-	-	840,000
Issue of warrants	-	(118,146)	-	118,146	-	-
Commitment to issue shares	-	-	(70,000)	-	-	(70,000)
Share issue costs	-	(440)	-	-	-	(440)
Comprehensive loss for the period	-	-	-	-	(802,310)	(802,310)
Balance at Mar. 31, 2016	1,897,511	\$ 39,294,315	\$ -	\$ 2,347,765	\$ (41,636,214)	\$ 5,866
Balance at July 1, 2016	1,967,513	\$ 39,656,113	\$ -	\$ 2,405,759	\$ (41,955,291)	\$ 106,581
Shares issued for cash	84,000	420,000	-	-	-	420,000
Issue of warrants	-	(56,564)	-	56,564	-	-
Commitment to issue shares	-	-	288,000	-	-	288,000
Comprehensive loss for the period	-	-	-	-	(742,022)	(742,022)
Balance at Mar. 31, 2017	2,051,513	\$ 40,019,549	\$ 288,000	\$ 2,462,323	\$ (42,697,313)	\$ 72,559

*The accompanying notes are an integral part of these condensed consolidated interim financial statements.*

**TERRABIOGEN TECHNOLOGIES INC.**  
**CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS**

For the Nine Months ended March 31  
(Expressed in Canadian Dollars)  
(Unaudited – prepared by management)

	<b>2017</b>	<b>2016</b>
<b>OPERATIONS</b>		
Net loss	\$ (742,022)	\$ (802,310)
Items not involving cash:		
Depreciation	53,780	67,615
Interest expense	2,929	2,037
Accretion on provision for dismantling	157	118
	<b>(685,156)</b>	<b>(732,540)</b>
Changes in non-cash working capital balances:		
Amounts receivable	154	16,407
Deposits and prepaid expenses	16,598	8,096
Inventory	-	(6,065)
Accounts payable and accrued liabilities	(43,229)	(59,616)
	<b>(711,633)</b>	<b>(773,718)</b>
Interest paid	(2,930)	(2,037)
<b>CASH USED IN OPERATING ACTIVITIES</b>	<b>(714,563)</b>	<b>(775,755)</b>
<b>INVESTING</b>		
Cash received on sale of assets	-	1,042
Purchase of property and equipment	(5,283)	(3,041)
<b>CASH USED IN INVESTING ACTIVITIES</b>	<b>(5,283)</b>	<b>(1,999)</b>
<b>FINANCING</b>		
Shares issued for cash (net of issue costs)	420,000	769,560
Cash received for commitment to issue shares	288,000	-
<b>CASH PROVIDED BY FINANCING ACTIVITIES</b>	<b>708,000</b>	<b>769,560</b>
Increase (decrease) in cash	(11,846)	(8,194)
Cash, beginning of period	176,855	34,296
<b>CASH AND CASH EQUIVALENTS, end of period</b>	<b>\$ 165,009</b>	<b>\$ 26,102</b>

*The accompanying notes are an integral part of these condensed consolidated interim financial statements.*

**TERRABIOGEN TECHNOLOGIES INC.**  
**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
For the Nine Months Ended March 31, 2017  
(Expressed in Canadian Dollar)

---

**1. NATURE OF OPERATIONS AND GOING CONCERN**

TerraBioGen Technologies Inc. was incorporated in British Columbia, Canada, on August 17, 1993.

The Company has identified active ingredients that impart growth promotion, increased yields, and abiotic and biotic stress tolerance in plants, and is planning to commercialize this technology. In recent years, the company has increased its research and development capabilities including the construction of a lab scale pilot line. The facility in Burnaby, BC is used exclusively for strain screening and development, product formulation, growth room and greenhouse trials, and production of materials for field trials.

These unaudited condensed consolidated interim financial statements have been prepared on a going concern basis. At March 31, 2017, the Company had a working capital deficiency of \$99,869 (March 31, 2016 – (\$234,786)), an accumulated deficit of \$42,697,313 (March 31, 2016 - \$41,636,214), and a net cash outflow from operating activities of \$714,563 for the nine months then ended (2016 - \$775,755). These conditions indicate the existence of a material uncertainty which may cast significant doubt about the Company's ability to continue as a going concern. The Company's ability to continue its operations and to realize assets at their carrying values is dependent upon the continued support of its major shareholders, and ultimately, generating profitable operations and positive operating cash flows. Failure to obtain sufficient financing or other appropriate arrangements would require the Company's assets and liabilities to be restated on a liquidation basis which may differ significantly from the going concern basis. These unaudited condensed consolidated interim financial statements do not give effect to any adjustments or disclosures which would be necessary should the Company be unable to continue as a going concern.

The address of the Company's corporate office and principal place of business is 8536 Baxter Place, Burnaby, BC V5A 4T8.

**2. BASIS OF PRESENTATION**

**Basis of Presentation**

The unaudited condensed consolidated interim financial statements were prepared using the same accounting policies and methods as those in the Company's consolidated financial statements for the year ended June 30, 2016. These unaudited condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34, *Interim Financial Reporting*. Accordingly, certain disclosures normally included in annual financial statements prepared in accordance with International Financial Reporting Standards have been omitted or condensed.

Certain comparative amounts have been reclassified to conform with the financial statement presentation adopted for the current year.

These condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended June 30, 2016.

**Approval of the Financial Statements**

These unaudited condensed consolidated interim financial statements were approved for issuance by the Board of Directors on May 23, 2017.

**TERRABIOGEN TECHNOLOGIES INC.**  
**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
For the Nine Months Ended March 31, 2017  
(Expressed in Canadian Dollar)

---

**2. BASIS OF PRESENTATION** (continued)

**Use of estimates**

The preparation of these condensed consolidated financial statements, in compliance with IFRS, requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. Significant areas requiring the use of management estimates include the fair value of property and equipment, deferred income tax asset valuations, provision for dismantling, and fair value measurements for financial instruments and share-based compensation. Actual results could differ from those estimates.

**3. BANK LOAN**

The Company has a loan agreement with HSBC Bank Canada under a credit facility. The credit facility consists of a \$100,000 operating loan which bears interest at the bank's prime rate plus 1.25% per annum and is payable on demand. The loan is secured by a general security agreement providing a first security interest in all of the Company's assets and ranks ahead of all other loans. As at March 31, 2017 and as at June 30, 2016, the Company had no outstanding drawings against this credit facility.

**4. SHARE CAPITAL**

Authorized Share Capital

The Company has authorized share capital of an unlimited number of common shares without par value and an unlimited number of preferred shares without par value. There have been no preferred shares issued as at March 31, 2017.

**Issued and outstanding: See Consolidated Statement of Changes in Shareholders' Equity**

Since July 1, 2015, the following share transactions occurred:

- a) On July 13, 2015, the Company issued 42,000 units at \$10.00 per unit for gross proceeds of \$420,000. Each unit consists of one common share and one warrant exercisable at \$12.00 per share until July 12, 2020.
- b) On December 29, 2015, the Company issued 84,000 units at \$5.00 per unit for gross proceeds of \$420,000. Each unit consists of one common share and one warrant exercisable at \$6.00 per share until December 28, 2020.
- c) On May 6, 2016, the Company issued 70,002 units at \$6.00 per unit for gross proceeds of \$420,012. Each unit consists of one common share and one warrant exercisable at \$7.50 per share until May 5, 2021.
- d) On January 24, 2017, the Company issued 84,000 units at \$5.00 per unit for gross proceeds of \$420,000. Each unit consists of one common share and one warrant exercisable at \$6.00 per share until January 23, 2022.



**TERRABIOGEN TECHNOLOGIES INC.**  
**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
For the Nine Months Ended March 31, 2017  
(Expressed in Canadian Dollar)

**4. SHARE CAPITAL** (continued)

**Warrants** – Details of share purchase warrants during the periods ended March 31, 2017 and June 30, 2016 are as follows:

	Nine Months Ended Mar. 31, 2017		Year Ended June 30, 2016	
	Number	Weighted Average Exercise Price	Number	Weighted Average Exercise Price
Outstanding, beginning of year	<b>593,125</b>	<b>\$ 10.62</b>	397,123	\$ 12.00
Issued	<b>84,000</b>	<b>6.00</b>	196,002	7.82
Outstanding, end of year	<b><u>677,125</u></b>	<b><u>\$ 10.05</u></b>	<u>593,125</u>	<u>\$ 10.62</u>

As at March 31, 2017, the Company had share purchase warrants outstanding and exercisable as follows:

Number of Warrants Outstanding and Exercisable		Exercise Price per Share	Expiry Date	Weighted average Remaining Life
Mar. 31, 2017	June 30, 2016			
<b>90,000</b>	90,000	\$12.00	March 7, 2018	0.93 years
<b>46,000</b>	46,000	\$12.00	May 31, 2018	1.17 years
<b>43,000</b>	43,000	\$12.00	Sept. 5, 2018	1.43 years
<b>42,000</b>	42,000	\$12.00	Oct. 25, 2018	1.57 years
<b>8,123</b>	8,123	\$12.00	Oct. 31, 2018	1.58 years
<b>21,000</b>	21,000	\$12.00	Jan. 22, 2019	1.81 years
<b>21,000</b>	21,000	\$12.00	April 24, 2019	2.07 years
<b>21,000</b>	21,000	\$12.00	June 10, 2019	2.20 years
<b>21,000</b>	21,000	\$12.00	Sept. 8, 2019	2.44 years
<b>42,000</b>	42,000	\$12.00	Dec. 28, 2019	2.75 years
<b>42,000</b>	42,000	\$12.00	Feb. 18, 2020	2.89 years
<b>42,000</b>	42,000	\$12.00	July 12, 2020	3.29 years
<b>84,000</b>	84,000	\$6.00	Dec. 28, 2020	3.75 years
<b>70,002</b>	70,002	\$7.50	May 5, 2021	4.10 years
<b>84,000</b>	-	\$6.00	Jan. 23, 2022	4.82 years
<b><u>677,125</u></b>	<u>593,125</u>			<b><u>2.71 years</u></b>

**TERRABIOGEN TECHNOLOGIES INC.**  
**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
For the Nine Months Ended March 31, 2017  
(Expressed in Canadian Dollar)

**4. SHARE CAPITAL** (continued)

**Warrants** (continued)

The Company uses the Black-Scholes pricing model to estimate the fair value of share purchase warrants. The fair value of the warrants as estimated using the Black-Scholes pricing model also considers a discount factor due to the lack of liquidity of the warrants. The model requires management to make estimates which are subjective and may not be representative of actual results. Changes in assumptions can materially affect estimates of fair values. For purposes of the calculation, the following weighted average assumptions were used:

	<u>Nine months ended Mar. 31, 2017</u>	<u>Year ended June 30, 2016</u>
Risk-free interest rate	1.11%	0.75%
Expected dividend yield	0%	0%
Expected stock price volatility	47%	49%
Expected life of warrants	5.00 years	5.00 years

The weighted average fair value of the warrants issued during the period was \$0.67 (2016 - \$0.94).

**Stock options**

The Company grants stock options to directors, officers, employees and consultants as compensation for services, pursuant to its Incentive Stock Option Plan (the "Plan") instituted in 1999 and amended, most recently in November 2016. Options issued pursuant to the Plan have an exercise price as determined by the Board. Options have a maximum expiry period of ten years from the grant date. The number of options, which may be issued under the plan, is limited to no more than 10% of the Company's issued and outstanding shares on the grant date. The aggregate number of options granted to any one optionee in a twelve-month period is limited to 5% of the Company's issued shares at the time the options are granted. Options granted under the plan are subject to vesting terms determined by the Board.

A summary of the Company's share options at March 31, 2017 and June 30, 2016 and the changes for the periods ended on those dates is presented below:

	<u>Nine months ended March 31, 2017</u>		<u>Year ended June 30, 2016</u>	
	Options Outstanding	Weighted Average Exercise Price	Options Outstanding	Weighted Average Exercise Price
Opening balance	5,000	\$12.00	38,000	\$12.00
Forfeited or expired	(5,000)	(12.00)	(33,000)	(12.00)
Ending balance	-	-	5,000	\$12.00

**TERRABIOGEN TECHNOLOGIES INC.**  
**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
For the Nine Months Ended March 31, 2017  
(Expressed in Canadian Dollar)

---

**4. SHARE CAPITAL** (continued)

**Stock Options** (continued)

The Company had no share options outstanding and exercisable at March 31, 2017.

**5. RELATED PARTY TRANSACTIONS**

Related party transactions during the nine months ended March 31, 2017:

- a) Consulting fees of \$4,000 (2015 - \$13,100) were expensed for services provided by a company controlled by an officer.
- b) Accounts payable and accrued expenses included \$4,800 (2016 - \$1,800) of fees payable to directors. Fees to directors of \$10,600 (2016 - \$8,000) were expensed during the nine months, and \$9,600 (2016 - \$10,200) of fees were paid to directors during the nine months ended March 31, 2017.

**6. COMMITMENTS**

In the year ended June 30, 2013, the Company signed a lease for its current premises located in Burnaby, British Columbia. The lease is for a four-year term which expires on May 31, 2017 with a renewal option. The Company has exercised the option to renew and signed a lease extension for an additional four-year term which expires on May 31, 2021. Under the new lease, the lease rate will change from the current rate of \$13.00 per square foot to \$13.50 per square foot in year one and two and \$14.00 per square foot in year three and four. The landlord granted five months of free rent throughout the duration of the new lease.

The remaining commitment for rent and operating costs in the current year is \$25,881 and \$509,057 for the remainder of the renewal term; the Company paid a security deposit of \$7,612 which will be applied against the final month's rent.

**7. GOVERNMENT ASSISTANCE**

The Company receives government assistance under a number of government programs. Under these programs, the Company had signed contribution agreements with a maximum contribution of \$178,300 and expiry dates ranging from April 21, 2017 to November 30, 2017. During the nine months ended March 31, 2017, the Company filed claims for \$59,725 and all of these amounts have been received. The Company anticipates that it will claim the full remaining contribution amount of \$118,575.

**8. SUBSEQUENT EVENT**

Subsequent to March 31, 2017, the Company closed a non-brokered private placement of 192,000 units for gross proceeds of \$576,000; \$288,000 of these proceeds were received before March 31, 2017. Each Unit will consist of one common share and one warrant exercisable at \$5.00 per share expiring in five years.

At the February 24, 2017 board meeting, the board approved the granting of 177,000 options to staff, directors and officers and these options will be issued in the quarter ending June 30, 2017.

**TERRABIOGEN TECHNOLOGIES INC.  
MANAGEMENT DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED MARCH 31, 2017**

---



**TERRABIOGEN TECHNOLOGIES INC.**

**MANAGEMENT DISCUSSION & ANALYSIS**

**For the nine months ended March 31, 2017**

**TERRABIOGEN TECHNOLOGIES INC.**  
**MANAGEMENT DISCUSSION AND ANALYSIS**  
**FOR THE NINE MONTHS ENDED MARCH 31, 2017**

---

This discussion and analysis of financial position and results of operations is prepared as at May 23, 2017. The Management's Discussion and Analysis ("MD&A") should be read in conjunction with the audited consolidated financial statements of TerraBioGen Technologies Inc. (the "Company") as at and for the year ended June 30, 2016 and the unaudited condensed consolidated financial statements for the nine months ended March 31, 2017 and related notes thereof which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. Except as otherwise disclosed, all dollar figures included therein and the following MD&A are quoted in Canadian dollars. Additional information relevant to the Company's activities can be found on SEDAR at [www.sedar.com](http://www.sedar.com) or the Company's website at [www.terrabiogen.com](http://www.terrabiogen.com).

**Forward Looking Statements**

Certain information included in this discussion may constitute forward-looking statements. Forward-looking statements are based on current expectations and entail various risks and uncertainties. These risks and uncertainties could cause or contribute to actual results that are materially different than those expressed or implied. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "plan," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Readers are cautioned regarding statements discussing profitability; growth strategies; anticipated trends in our industry; our future financing plans; and our anticipated needs for working capital.

While it is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by us include: inability or delays in achieving its technical development and commercialization milestones, environmental factors that could impact the Company's product field trial performance, delays in achieving regulatory approval of its products, inability or delays in securing the necessary funding to complete the development and commercialization of its products.

The Company disclaims any obligation or intention to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required to do so by law.

**Description of the Business**

TerraBioGen Technologies Inc. was incorporated in British Columbia, Canada, on August 17, 1993. The Company's common shares were traded on the TSX Venture Exchange until June 11, 2012 when they were delisted at the Company's request.

The Company has developed microbial metabolite bioactive materials that improve plant health and yield, and impart biotics and abiotic stress tolerance in plants. The Company is in the process of commercializing this technology. In recent years, the company has increased its research and development capabilities including a lab scale pilot line. The facility in Burnaby, BC is used exclusively for strain screening and development, product formulation, growth room and greenhouse trials, and production of materials for field trials and commercialization.

The Company is committed to research and development to continue to improve the effectiveness of its technologies, the quality of its products, and the creation of new product lines. Through collaborations with some of the leading agricultural institutes in North America and funding from Canadian national and provincial government programs, TerraBioGen is developing and testing microbial derived bioactive materials that are responsible for the improved crop yields and increase stress tolerance in a wide range of plant varieties. Further, the Company is taking steps to secure intellectual property rights to these bioactive materials and to formulate them in order to fully commercialize their potential.

**TERRABIOGEN TECHNOLOGIES INC.  
MANAGEMENT DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED MARCH 31, 2017**

**Overall Performance**

The Company is a development company with minimal revenues to date from its activities.

**Quarterly Financial Results**

	Year ended June 30, 2017			Year ended June 30, 2016				Year ended June 30, 2015
	Jan- Mar/17 <b>Q3 2017</b>	Oct- Dec/16 <b>Q2 2017</b>	Jul- Sep/16 <b>Q1 2017</b>	Apr- Jun/16 <b>Q4 2016</b>	Jan- Mar/16 <b>Q3 2016</b>	Oct- Dec/15 <b>Q2 2016</b>	Jul- Sep/15 <b>Q1 2016</b>	Apr- Jun/15 <b>Q4 2015</b>
Revenues	\$ -	\$ -	\$ -	\$ -	\$ 1,219	\$ 3,501	\$ -	\$ -
Loss before other income (expense)	(259,571)	(281,276)	(198,260)	(318,686)	(277,228)	(275,113)	(251,836)	(325,660)
Net finance expense	(838)	(788)	(1,289)	(532)	(752)	(553)	(420)	(364)
Gain/loss on sale of assets	-	-	-	140	3,685	(92)	-	-
Net Loss	(260,409)	(282,064)	(199,549)	(319,078)	(274,295)	(275,758)	(252,256)	(326,024)
Net Loss per share (basic and diluted)	\$ (0.13)	\$ (0.14)	\$ (0.10)	\$ (0.16)	\$ (0.15)	\$ (0.15)	\$ (0.14)	\$ (0.19)
	<b>Mar. 31/17</b>	<b>Dec. 31/16</b>	<b>Sept. 30/16</b>	<b>June 30/16</b>	<b>Mar. 31/16</b>	<b>Dec. 31/15</b>	<b>Sept. 30/15</b>	<b>June 30/15</b>
Total assets	\$ 358,131	\$ 209,513	\$ 237,509	\$ 435,226	\$ 289,626	\$ 585,932	\$ 441,346	\$ 381,874
Long term liabilities	6,407	6,368	6,329	6,251	6,251	6,211	6,172	6,133

**Comparison of the nine months ended March 31, 2017 to the nine months ended March 31, 2016**

There was no revenue recorded in the nine months ending March 31, 2017. During the nine months ending March 31, 2016, the Company recorded revenue of \$4,720 and gross profit of \$4,322.

During the nine months ended March 31, 2017, the Company recorded total expenses of \$739,107, compared to \$808,500 in the prior year, a decrease of \$69,393. Administration costs decreased by \$29,133, and research and development costs decreased by \$40,260.

The administration cost decrease was due to a \$19,820 decrease in travel costs and a \$9,012 decrease in office expenses resulting from the Company reducing discretionary spending. The research and development decrease was largely due to an \$11,569 decrease in depreciation, a \$9,086 decrease in supplies and a \$19,735 increase in government funding.

During the nine months ended March 31, 2017, the Company incurred interest expenses of \$2,929 and earned interest income of \$14, resulting in a net loss for the nine months of \$742,022 or \$0.37 per share. In the previous year, the Company incurred interest expenses of \$2,037 and earned interest income of \$312, and realized a gain of \$3,593 on the sale of assets, resulting in a net loss of \$802,310 or \$0.44 per share.

**Comparison of the three months ended March 31, 2017 to the three months ended March 31, 2016**

There was no revenue recorded in the three months ending March 31, 2017. During the three months ending March 31, 2016, the Company recorded revenue and gross profit of \$1,219.

During the three months ended March 31, 2017, the Company recorded total expenses of \$259,571, compared to \$278,448 in the prior year, a decrease of \$18,877. Administration costs decreased by \$6,145 and research and development costs decreased by \$12,732.

**TERRABIOGEN TECHNOLOGIES INC.  
MANAGEMENT DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED MARCH 31, 2017**

The administration cost decrease was due to a decrease in travel expenses resulting from a reduction in attending conferences. The research and development cost decrease was largely due to an increase in government funding.

During the three months ended March 31, 2017, the Company incurred interest expenses of \$838, resulting in a net loss for the three months of \$260,409 or \$0.13 per share. In the previous year, the Company incurred interest expenses of \$825 and earned interest income of \$73, and realized a gain of \$3,685 on the sale of assets, resulting in a net loss of \$274,296 or \$0.15 per share.

**Breakdown of Expenses**

	2017	2016
<b>ADMINISTRATION:</b>		
Wages and management fees	\$ 156,200	\$ 169,244
Depreciation	20,829	23,095
Accretion for provision for dismantling	157	117
Professional fees	21,179	11,042
Office expenses	80,663	89,675
Directors fees and expenses	10,707	7,569
Travel & entertainment	3,591	23,411
Regulatory fees	10,629	8,935
	<b>\$ 303,955</b>	<b>\$ 333,088</b>
<b>RESEARCH AND DEVELOPMENT:</b>		
Wages and benefits	\$ 264,754	\$ 271,104
Contractors	21,027	21,883
Growing trials	28,574	28,490
Rent and utilities	99,783	92,531
Depreciation	32,951	44,520
Other expenses	47,788	56,874
Government assistance	(59,725)	(39,990)
	<b>\$ 435,152</b>	<b>\$ 475,412</b>

**Liquidity and Capital Resources**

During the nine months ended March 31, 2017, the Company spent \$719,846 in cash on operating and investing activities, and realized \$708,000 from financing activities, for a net cash outflow of \$11,846, leaving a \$165,009 net cash balance at March 31, 2017.

At March 31, 2017, the Company had total liabilities of \$285,572, a decrease of \$43,073 from June 30, 2016. The Company had a working capital deficit of \$99,869 compared to a deficit of \$114,500 at June 30, 2016. There are no committed capital expenditures required to meet the Company's planned research and development efforts. The Company has a 4 year lease on its premises in Burnaby, expiring on May 31, 2017 and has signed a four year lease extension, expiring May 31, 2021. Under the new lease, the lease rate will change from the current rate of \$13.00 per square foot to \$13.50 per square foot in year one and two and \$14.00 per square foot in year three and four. The landlord granted five months of free rent throughout the duration of the new lease. The remaining commitment for rent and operating costs in the current year is \$25,881 and \$509,057 for the remainder of the four year renewal term; the Company paid a security deposit of \$7,612 which will be applied against the final month's rent.

**TERRABIOGEN TECHNOLOGIES INC.**  
**MANAGEMENT DISCUSSION AND ANALYSIS**  
**FOR THE NINE MONTHS ENDED MARCH 31, 2017**

---

The Company is dependent on cash from new financing activities and a \$100,000 bank line of credit in order to meet its obligations. Until the Company generates significant sales, it will be relying on new financing and any difficulty in raising new funds from these activities will have a significant impact on the Company's ability to operate. The Company anticipates that it will be able to raise new financing to cover its operating needs through private placements.

**Share Capital**

As at May 23, 2017, the Company has 2,051,513 common shares issued and outstanding for a total of \$40,019,549 in share capital. There are 677,125 warrants exercisable into common shares at a weighted average exercise price of \$10.05 and there are no outstanding stock options.

**Off Balance Sheet Arrangements**

To the best of management's knowledge, there are no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the results of operations or financial condition of the Company.

**Business Development**

The Company's primary focus has been the development, formulation and launch of its first generation product, TerraBioGen LCFX. The Company has pre-marketed LCFX to select, influential Canadian commercial greenhouse vegetable growers. Based on the results of the pre-market trials, the Company is further improving its formulations to optimize performance. Through funding provided by Agriculture and Agri-Food Canada and the BC Ministry of Agriculture through the Canada-BC Agri-Innovation Program under Growing Forward 2, the company is conducting demonstration trials on a variety of crop in the floriculture industry. The Company is also developing further geographic markets for LCFX and microbial products in the United States of America and select markets in the European Union. To support the launch of LCFX, the Company is collaborating with the University of Guelph and McMaster University in understanding the mechanism of action of its bioactive materials.

The Company continues to conduct extensive research on its next generation of microbial metabolite bioactive materials through strain development and characterization, process optimization and formulation. The Company is working closely with grower/cooperator partners to ensure that the products are well formulated and effective.

The Company is continuing a comprehensive, focused field trial program in 2016-17 in order to optimize product formulation and application, delivering benefits to the grower and substantive return to the Company. Trials will cover select varieties of both horticultural and agricultural crops.

**Patents**

In September 2016, the Company filed a provisional patent with the US Patent and Trademark Office for its lead strain with claims covering production process and product formulation, and product application and performance on a wide variety of crops. The Company has until September 2017 to file the full patent with the USPTO and PCT. The Company anticipates filing further provisional patents in 2017.

**Transactions with Related Parties**

During the nine months ended March 31, 2017, the Company paid fees of \$4,000 for accounting and financial services to a company controlled by an officer. Also, directors receive a fee of \$200 for each meeting or committee meeting attended; directors' fees of \$10,600 were expensed during the nine months ended March 31, 2017 and \$9,600 of fees were paid to directors. There were \$4,800 in fees payable to directors at March 31, 2017.

**Critical Accounting Estimates and Judgments**

The preparation of these consolidated financial statements requires management to make certain critical accounting estimates and assumptions that affect the application of accounting policies and the reported amount of assets, liabilities, income and expenses. It also requires management to exercise judgment in applying the Company's



**TERRABIOGEN TECHNOLOGIES INC.**  
**MANAGEMENT DISCUSSION AND ANALYSIS**  
**FOR THE NINE MONTHS ENDED MARCH 31, 2017**

---

accounting policies. Significant areas requiring the use of management estimates include the fair value measurements for equity instruments. Actual results could differ from those estimates.

Information about assumptions and estimation uncertainties in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are included in the following notes:

- Note 11 Share capital – fair value measurements for equity instruments

Information about critical judgments that management has made in applying the Company's accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements include the going concern assessment, the classification of financial instruments, the applicability of government assistance programs, and the determination of cash generating units for purposes of impairment testing.

### **Changes in Accounting Policies**

#### **New standards and interpretations not yet adopted**

The following is an overview of accounting standard changes that the Company will be required to adopt in future years. The Company does not expect to adopt any of these standards before their effective dates. The Company continues to evaluate the impact of these standards on its consolidated financial statements.

(a) IFRS 9 - Financial Instruments:

On July 24, 2014 the IASB issued the complete IFRS 9 (IFRS 9 (2014)).

IFRS 9 (2014) introduces new requirements for the classification and measurement of financial assets. Under IFRS 9 (2014), financial assets are classified and measured based on the business model in which they are held and the characteristics of their contractual cash flows.

The standard introduces additional changes relating to financial liabilities.

It also amends the impairment model by introducing a new 'expected credit loss' model for calculating impairment.

IFRS 9 (2014) also includes a new general hedge accounting standard which aligns hedge accounting more closely with risk management.

The mandatory effective date of IFRS 9 is for annual periods beginning on or after January 1, 2018 and must be applied retrospectively with some exemptions. Early adoption is permitted. The restatement of prior periods is not required and is only permitted if information is available without the use of hindsight.

The Company intends to adopt IFRS 9 (2014) in its financial statements for the annual period beginning on July 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.

(b) IFRS 15 Revenue from Contracts with Customers

On May 28, 2014 the IASB issued IFRS 15 Revenue from Contracts with Customers. The new standard is effective for annual periods beginning on or after January 1, 2017. On July 22, 2015, the IASB deferred the effective date of this standard to January 1, 2018 with earlier adoption permitted. The Company is currently evaluating the impact of IFRS 15 on its financial statements.

The standard contains a single model that applies to contracts with customers and two approaches to recognizing revenue: at a point in time or over time. The model features a contract-based five-step analysis of transactions to determine whether, how much and when revenue is recognized. New estimates and judgmental thresholds have been introduced, which may affect the amount and/or timing of revenue recognized.

**TERRABIOGEN TECHNOLOGIES INC.**  
**MANAGEMENT DISCUSSION AND ANALYSIS**  
**FOR THE NINE MONTHS ENDED MARCH 31, 2017**

---

The Company intends to adopt IFRS 15 in its financial statements for the annual period beginning on July 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.

(c) IFRS 16 Leases

In January 2016, the IASB issued IFRS 16 – Leases, which supersedes IAS 17 – Leases. IFRS 16 establishes principles for the recognition, measurement presentation and disclosure of leases. The standard establishes a single model for lessees to bring leases on balance sheet while lessor accounting remains largely unchanged and retains the finance and operation lease distinctions. IFRS 16 is effective for annual periods beginning on or after January 1, 2019 with earlier adoption permitted, but only if also applying IFRS 15 – Revenue from Contracts with Customers. The Company is currently evaluating the impact of IFRS 16 on its financial statements.

**Financial Instruments**

The Company's financial instruments consist of cash, amounts receivable and accounts payables and accrued liabilities. The fair values of these financial instruments approximate carrying value because of their short-term nature. Cash and government grants receivable are classified as loans and receivables, which are measured at amortized cost. Accounts payable, accrued liabilities and customer deposits are classified as other financial liabilities and are measured at amortized cost.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

*Foreign exchange risk*

Most of the Company's operating expenditures are denominated in Canadian dollars and certain operating expenses are in United States dollars. The Company's exposure to foreign currency risk arises primarily on fluctuations between the Canadian dollar and the United States dollar.

The Company has not entered into any derivative instruments to manage foreign exchange fluctuations.

At March 31, 2017 and June 30, 2016, a change of 10% +/- in the US dollar would not result in a significant impact in the statements of loss and comprehensive loss.

*Interest rate risk*

The Company is subject to interest on its bank loans which are at negotiated rates of interest. Significant increase in these interest rates would result in increased costs for the Company.

*Credit risk*

Credit risk is the risk of an unexpected loss if a counterparty to a financial instrument fails to meet its contractual obligations. The credit risk associated with cash is believed to be minimal as cash is on deposit with Canadian banks that are believed to be creditworthy. Amounts receivable is comprised primarily of amounts due from the Government of Canada. The Company does not believe it is exposed to significant credit risk.

*Liquidity risk*

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure and financial leverage as outlined above.

The Company monitors its ability to meet its short-term operating expenditures by raising additional funds through share issuance when required. All of the Company's financial liabilities have contractual maturities of 30 days or are subject to normal trade terms.

**TERRABIOGEN TECHNOLOGIES INC.  
MANAGEMENT DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED MARCH 31, 2017**

---

**Reclassifications**

Certain comparative figures have been reclassified to conform with the financial statement presentation adopted for the current year.

**Additional Information**

Additional information about TerraBioGen Technologies Inc. can be found on SEDAR at [www.sedar.com](http://www.sedar.com) or on the Company's website at [www.TerraBioGen.com](http://www.TerraBioGen.com).